Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
559 hedge funds and large institutions have $26B invested in Alexion Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 72 funds opening new positions, 254 increasing their positions, 178 reducing their positions, and 68 closing their positions.
47% more call options, than puts
Call options by funds: $675M | Put options by funds: $459M
43% more repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 178
12% more funds holding in top 10
Funds holding in top 10: 17 → 19 (+2)
6% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 68
0% more capital invested
Capital invested by funds: $26B → $26B (+$69.5M)
0% less funds holding
Funds holding: 561 → 559 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$411M |
| 2 |
Goldman Sachs
New York
|
+$377M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$234M |
| 4 |
BlackRock
New York
|
+$151M |
| 5 |
TP
Third Point
New York
|
+$145M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.04B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$655M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$290M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$215M |
| 5 |
JP Morgan Chase
New York
|
-$205M |
ALXN Hedge Fund Activity: Q2 2017 in Review
559 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2017, worth a combined $26B — up 0.27% from $26B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new ALXN positions and 68 closed out — a net gain of 4 holders — while 254 added to existing stakes and 178 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $411M. The largest seller was Jennison Associates, cutting an estimated $1.04B.
- 559 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2017, down from 561 in Q1 2017.
- Funds reported $26B of Alexion Pharmaceuticals stock for Q2 2017, up 0.27% quarter-over-quarter.
- 72 funds opened new Alexion Pharmaceuticals positions in Q2 2017 and 68 closed out, a net change of +4 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2017 was T. Rowe Price Associates, an estimated $411M added.
- The largest Alexion Pharmaceuticals seller in Q2 2017 was Jennison Associates, an estimated $1.04B sold.
Based on aggregated 13F filings for Q2 2017.